| SHIONOGI & CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135997 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND - The present invention provides, for example, the following compounds as a pharmaceutical composition for treating diseases induced by production, secretion or deposition of amyloid β proteins. | 05-31-2012 |
| 20120130070 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY - This invention provides a compound of the formula (I): | 05-24-2012 |
| 20120123114 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY - A compound which inhibits both of EGF receptor tyrosine kinase and HER2 tyrosine kinase is provided. | 05-17-2012 |
| 20120108575 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF - The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound. | 05-03-2012 |
| 20120093808 | HUMANIZED PCRV ANTIBODY HAVING ANTI-PSEUDOMONAL ACTIVITY - Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with | 04-19-2012 |
| 20120071475 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY - Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof. | 03-22-2012 |
| 20120066777 | TEST AGENT FOR VISCERAL OBESITY AND USE THEREOF - Disclosed are: a method for detecting (diagnosing) visceral obesity in a subject; a test agent useful for the method; a method for searching for a substance that can be used as an active ingredient for ameliorating visceral obesity; and an ameliorating agent for visceral obesity or a medicinal agent for preventing a metabolic disease developed as a result of the progression of visceral obesity. As the test agent, a polynucleotide which comprises at least 15 nucleotides and can hybridize with a nucleotide sequence for coiled-coil domain containing protein 3 (CCDC3) gene or a nucleotide sequence complementary to the nucleotide sequence under stringent conditions or an antibody capable of recognizing CCDC3 protein is used. | 03-15-2012 |
| 20120040375 | ANTI-MUC1 ANTIBODY - An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1. | 02-16-2012 |
| 20120035242 | PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY OR DIABETES - The invention is intended to provide a pharmaceutical composition for treating or preventing obesity or type II diabetes and a method for treatment for them. A pharmaceutical composition comprising an Acsl-1 inhibitor of this invention as an active ingredient is useful for prevention or treatment of obesity or type II diabetes. | 02-09-2012 |
| 20120022249 | AMINODIHYDROTHIAZINE DERIVATIVES - A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): | 01-26-2012 |
| 20120022069 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF - The invention relates to acrylamide compounds of Formula I mentioned below. | 01-26-2012 |
| 20120021431 | DIAGNOSTIC METHODS USING BNP - The present invention provides a new method and kit for determining the overload of atrium or ventricle in a subject comprising at least a step of measuring levels of proBNP-108 in a sample from the subject. The disclosed methods and kits are useful, for example, in the diagnosis, prevention and/or treatment of cardiac diseases, particularly heat failure, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, and atrial fibrillation. | 01-26-2012 |
| 20120016116 | AMINODIHYDROTHIAZINE DERIVATIVES - A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): | 01-19-2012 |
| 20120015961 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY - The present invention provides, for example, a compound of the following formula (I): | 01-19-2012 |
| 20120010428 | PROCESS FOR THE PREPARATION OF SULFOMATE-CARBOXYLATE DERIVATIVES - Disclosed is a process for the preparation of Compound (III), salt or solvate thereof by reacting Compound (I), salt or solvate thereof with Compound (II) in a toluene solvent in the presence of an additive such as water or an alcohol. Also disclosed is a process for the preparation of Compound (IV) comprising hydrolyzing the obtained Compound (III) if necessary, and then oxidizing. | 01-12-2012 |
| 20120004227 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM - The present invention discloses novel cyclohexane derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), or a pharmaceutically acceptable salt or a solvate thereof: | 01-05-2012 |
| 20110319412 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM - The present invention discloses novel piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), a pharmaceutically acceptable salt or a solvate thereof: | 12-29-2011 |
| 20110294813 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 - Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. | 12-01-2011 |
| 20110293670 | ADHESIVE MATERIAL CONTAINING 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - There is provided an adhesive preparation containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive preparation is a 5-methyl-1-phenyl-2-(1H)-pyridone-containing adhesive preparation including an active medicinal ingredient-containing layer, characterized in that the active medicinal ingredient-containing layer contains an lipophilic base, a dissolving agent (except glycerin and a medium-chain aliphatic acid triglyceride), and 5-methyl-1-phenyl-2-(1H)-pyridone or medically acceptable salts thereof. | 12-01-2011 |
| 20110269971 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE - Disclosed is a process for producing 1-hydroxy-4-aminoadamantane. | 11-03-2011 |
| 20110263855 | PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS - Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P | 10-27-2011 |
| 20110251386 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE - Disclosed is a compound which is useful as an endothelial lipase inhibitor. | 10-13-2011 |
| 20110251266 | APTAMER FOR NGF AND USE THEREOF - Provided are an aptamer having an inhibitory activity against NGF; a complex containing an aptamer having a binding activity or inhibitory activity against NGF and a functional substance (e.g., affinity substances, labeling substances, enzymes, drug delivery vehicles, drugs and the like); a medicament, a diagnostic agent, a labeling agent and the like containing an aptamer having a binding activity or inhibitory activity against NGF, or a complex containing the aptamer and the functional substance; and the like. | 10-13-2011 |
| 20110251212 | PIPERAZINE DERIVATIVES - A compound which specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist is provided. | 10-13-2011 |
| 20110237576 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY - The present invention provides a compound which has an effect of inhibiting amyloid-β production and is useful as a therapeutic agent for diseases induced by production, secretion and/or deposition of amyloid-β proteins. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: | 09-29-2011 |
| 20110230472 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY - It is an object of the present invention to provide a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a ring-fused azole compound shown in the present specification, or a pharmaceutically acceptable salt thereof. | 09-22-2011 |
| 20110190279 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY - The following compound is provided as an agent for treating a disease induced by production, secretion and/or deposition of amyloid β protein, for example, a compound represented by the formula (I): | 08-04-2011 |
| 20110190254 | CEPHALOSPORIN HAVING CATECHOL GROUP - The present invention provides Cephem compounds which have a wide antimicrobial spectrum and have potent antimicrobial activity against beta-lactamase producing Gram negative bacteria as follows: | 08-04-2011 |
| 20110190236 | CHEMICAL COMPOUNDS - The present invention features compounds that are prodrugs of HIIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. | 08-04-2011 |
| 20110183939 | NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides a novel P2X | 07-28-2011 |
| 20110172415 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP - It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. | 07-14-2011 |
| 20110172217 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY - The present invention provides compounds or a pharmaceutically acceptable salt thereof which inhibit the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and are therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a ring-fused morpholine compound shown in the present specification, or a pharmaceutically acceptable salt thereof. | 07-14-2011 |
| 20110150896 | Antibody against PCRV - Provided is an effective means for therapy of infection, particularly infection with | 06-23-2011 |
| 20110111443 | APPARATUS FOR AUTO-PRETREATING SUGAR CHAIN - To provide an autoanalyzer for analyzing a sugar chain contained in a biological sample, in particular, serum. Namely, it is intended to provide a method of analyzing a sugar chain in a sample, which comprises the following steps: A) the sugar chain-releasing step of releasing the sugar chain in the sample; B) the detection sample-preparing step of preparing the released sugar chain for detection; and, in the case of conducting mass spectrometry using a plate, C) the step of forming a plate for the mass spectrometry having the captured sugar chain dotted thereon which comprises the step of providing the tagged sugar chain sample solution obtained in the step B) on a collection plate; and, if required, the step of conducting an operation in a solid phase support-enclosed plate to form the plate for mass spectrometry; and D) the step of analyzing the sugar chain to be assayed. | 05-12-2011 |
| 20110104276 | PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved. | 05-05-2011 |
| 20110097525 | Coating Material and Container Coated with the Coating Material - A coating material includes a first aqueous dispersion (A) and a second aqueous dispersion (B) wherein a dispersoid of the first aqueous dispersion (A) has an average particle diameter of 1 to 20 μm and a dispersoid of the second aqueous dispersion (B) has an average particle diameter 1/100 to 1/5 of that of the dispersoid of the first aqueous dispersion (A), and the mass ratio (the aqueous dispersion (A)/the aqueous dispersion (B)) of the dispersoid of the first aqueous dispersion (A) to the dispersoid of the second aqueous dispersion (B) is 2/1 to 100/1. Also provided is a container, which is coated with the coating material and has excellent properties. | 04-28-2011 |
| 20110065641 | POLYPEPTIDE AND DNA THEREOF USEFUL AS A NEOVASCULAR MARKER - A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided. | 03-17-2011 |
| 20110060145 | PROCESS FOR PRODUCTION OF COMPOUND HAVING ANTAGONISTIC ACTIVITY ON NPYY5 RECEPTOR, AND USEFUL CRYSTAL - Disclosed are process for producing a compound having NPYY5 receptor antagonism and useful crystals. | 03-10-2011 |
| 20110028499 | PHARMACEUTICAL COMBINATION COMPRISING VITAMIN K - It is found that compounds having PPARδ agonistic activity induced abnormal blood coagulation or muscular disorder. A pharmaceutical combination comprising vitamin K and a compound having PPARδ agonistic activity can prevent the abnormal blood coagulation. A pharmaceutical composition comprising vitamin K can prevent muscular disorder. | 02-03-2011 |
| 20110000938 | POWDER MATERIAL SUPPLY DEVICE - The present invention provides a powder material supply device, wherein a powder and/or granular material supplied to an inner cylinder | 01-06-2011 |
| 20100273842 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF - This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I): | 10-28-2010 |
| 20100273841 | AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF - This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I):
| 10-28-2010 |
| 20100267945 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY - A compound of the formula (I): | 10-21-2010 |
| 20100240711 | SOLID PREPARATION COMPRISING NPYY5 RECEPTOR ANTAGONIST - A preparation which can improve solubility of a NPYY5 receptor antagonist in water, even when the NPYY5 receptor antagonist is contained in the preparation at a high content is provided. A solid preparation containing a NPYY5 receptor antagonist, an amorphous stabilizer, and optionally an amorphousization inducing agent. Particularly, when the amorphous stabilizer is hydroxypropylmethylcellulose phthalate and/or hydroxypropylmethylcellulose acetate succinate, and the amorphousization inducing agent is urea and/or saccharine sodium at an addition amount of less than 8% by weight, dissolution out property of a water-hardly soluble NPYY5 receptor antagonist could be improved. | 09-23-2010 |
| 20100240659 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY - Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. | 09-23-2010 |
| 20100234363 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE - Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. | 09-16-2010 |
| 20100216726 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof - The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound. | 08-26-2010 |
| 20100197662 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY - Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: | 08-05-2010 |
| 20100189942 | Blister Packaging Multilayer Resin Film and Blister Package - A blister packaging multilayer resin film is used to produce a blister package in which an item is sealed between a support substrate and the multilayer resin film, wherein the multilayer resin film includes an oxygen barrier layer that is arranged on a side of the multilayer resin film which side faces the support substrate, and a moisture proof layer that is arranged on a side of the oxygen barrier layer which side does not face the support substrate. | 07-29-2010 |
| 20100160290 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE - A pharmaceutical composition for treating Alzheimer's disease containing a compound represented by the general formula (I); | 06-24-2010 |
| 20100155433 | POWDER MATERIAL SUPPLY DEVICE - The present invention provides a powder material supply device, wherein a powder and/or granular material supplied to an inner cylinder | 06-24-2010 |
| 20100119584 | MEDICATED PATCH COMPRISING 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - There is provided a medicated patch including 5-methyl-1-phenyl-2-(1H)-pyridone. A medicated patch comprising a percutaneously absorbable preparation layer, wherein the percutaneously absorbable preparation layer includes 5-methyl-1-phenyl-2-(1H)-pyridone or a pharmaceutically acceptable salt thereof as an active component, a dissolving agent and an aqueous base material (or a rubber-type base material), and the active component is contained in an amount of 0.1 to 30 mass % relative to the total amount of the percutaneously absorbable preparation layer. | 05-13-2010 |
| 20100113448 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 - Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. | 05-06-2010 |
| 20100105923 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE - Disclosed is a process for producing 1-hydroxy-4-aminoadamantane. | 04-29-2010 |
| 20100099676 | SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 - A compound represented by the general formula (I): | 04-22-2010 |
| 20100075957 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP - This invention provides a compound of the formula (I): | 03-25-2010 |
| 20100063027 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity - This invention provides a compound of the formula (I): | 03-11-2010 |
| 20100035996 | GLUCOSE METABOLISM STIMULATING AGENT - A compound of the formula I: | 02-11-2010 |
| 20090305409 | Liposome Capable of Effective Delivery of Given Substance Into Nucleus - Disclosed is a non-viral vector capable of delivering a given substance into the nucleus of a target cell effectively even when the target cells is a undividable cell such as a dendritic cell. A bilamellar liposome having a first lipid membrane and a second lipid membrane successively from the outside, the first lipid membrane having a membrane-fusing ability and the second lipid membrane having on its surface a nuclear transport peptide. | 12-10-2009 |
| 20090263858 | Process for synthesis of mucin-type peptides and muc1-related glycopeptides - The invention aims at providing novel compounds useful as primer in producing mucin-type glycopeptides which are useful in a wide field including materials for biochemical research, drugs, and food and the production of which was difficult in the prior art; and a process for the production of glycopeptides by using the primers. The aim is attained by providing novel glycopeptide derivatives (represented by the general formula (I)) which each bear an aldehyde or ketone group at the end and each contain an amino acid residue cleavable with a protease; and an easy and simple process for the production of glycopeptides by using the derivative as the primer. | 10-22-2009 |
| 20090221817 | PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXILIC ACID DERIVATIVES - A process for the preparation of Compound (I) comprising reacting Compound (II) with a base in an aprotic solvent, which is represented by the following scheme: | 09-03-2009 |
| 20090217627 | Production Method for Container Packing Filler and Tubular Net Rolling Apparatus - A method and an apparatus for producing a container packing filler are provided, which ensure that a net can be correctly and speedily rolled up into a bulk or ball shape. A stretchable tubular net (N) is fitted around a columnar support member ( | 09-03-2009 |
| 20090206245 | Mass analysis method using fine metal particles - It is an object of the present invention to provide a novel mass spectrometry method which overcomes the conventional problems mentioned above, which can analyze at a high sensitivity and high accuracy a chemical reaction on a surface of a self-organized membrane bound to a metal, and which can be applied to analysis of structures of a sugar chain in future. According to the present invention, a method for performing mass spectrometry of sulfur atom-containing derivatives of an organic residue, characterized in that the method includes ionizing a metal-organic residue complex into the derivatives, wherein the complex has the organic residue bound through a sulfur atom to the metal is provided, thereby solving the above problems. | 08-20-2009 |
| 20090203039 | MONOCLONAL ANTIBODY TO SOLUBLE LOX-1 - It is intended to provide a monoclonal antibody that specifically recognizes human soluble LOX-1, particularly a monoclonal antibody with a dissociation constant (Kd) for human soluble LOX-1 of 1×10 | 08-13-2009 |
| 20090170867 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA′ | 07-02-2009 |
| 20090170832 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY - Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. | 07-02-2009 |
| 20090143414 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity - A compound which inhibits both of EGF receptor tyrosine kinase and HER2 tyrosine kinase is provided. | 06-04-2009 |
| 20090137614 | Pharmaceutical combination comprising vitamin k - It is found that compounds having PPARδ agonistic activity induced abnormal blood coagulation or muscular disorder. A pharmaceutical combination comprising vitamin K and a compound having PPARδ agonistic activity can prevent the abnormal blood coagulation. A pharmaceutical composition comprising vitamin K can prevent muscular disorder. | 05-28-2009 |
| 20090136563 | Method for Coating Particle with Lipid Film - A method for coating an object, i.e. a particle, with two sheets of lipid film having a space formed there between. In the method for coating a particle having a positive electrostatic-charging property with two sheets of lipid film, the particle having a positive electrostatic-charging property is brought into contact with a plurality of SUV type liposomes having a negative electrostatic-charging property to form a complex having a negative electrostatic-charging property containing the particle having a positive electrostatic-charging property and the SUV type liposomes having a negative electrostatic-charging property coupled electrostatically with the particle having a positive electrostatic-charging property, and then the complex having a negative electrostatic-charging property is treated with cation. | 05-28-2009 |
| 20090131491 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I - Disclosed is a compound useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1. | 05-21-2009 |
| 20090111098 | REPORTER GENE ASSAY - The invention provides a more highly accurate assay for measuring the transcriptional activity of a test substance. Disclosed is a reporter gene assay, comprising the steps of contacting a cell having a vector wherein a reporter gene containing a gene encoding an epitope tag is ligated downstream to a recognition sequence of a transcription factor and a nucleotide sequence necessary for transcriptional initiation, with a test substance and detection antibodies; detecting a phenomenon caused by the two kinds of detection antibodies coming close to each other; and correlating the detected phenomenon with the effect of the test substance on transcriptional regulatory mechanism. | 04-30-2009 |
| 20090105312 | SOLID PREPARATION HAVING IMPROVED SOLUBILITY - A preparation which can improve the dissolution property of a poorly water soluble drug even when the drug is contained in the preparation at a high content is provided. | 04-23-2009 |
| 20090082560 | AMINODIHYDROTHIAZINE DERIVATIVES - A composition having BACE 1 inhibitory activity containing a compound represented by the general formula (I): | 03-26-2009 |
| 20090069304 | MMP-13 SELECTIVE INHIBITOR - Since it is thought that if the activity of MMP-13 can be inhibited, this will largely contribute to improvement or prevention of progession of pathological states, particularly, osteoarthritis (OA), resulting from or associated with the MMP-13 activity, the development of MMP-13 inhibitors is anticipated. There are provided a compound represented by the general formula (I): | 03-12-2009 |
| 20090062261 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP - It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. | 03-05-2009 |
| 20090043094 | PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVES - A process for the preparation of Compound (I) comprising reacting Compound (II) with a base in an aprotic solvent, which is represented by the following scheme: | 02-12-2009 |
| 20080274178 | Orally Disintegrating Tablet - By mixing an active ingredient, crystalline cellulose, an inorganic excipient, carmellose, and a lubricant at not more than 0.8% by weight per tablet, and compressing the mixture, or compressing the mixture by an external lubricating method, a palatable orally disintegrating tablet which maintains a tablet hardness and exhibits good disintegrating property can be obtained. | 11-06-2008 |
| 20080262264 | Process For the Preparation of Sulfomate-Carboxylate Derivatives - Disclosed is a process for the preparation of Compound (III), salt or solvate thereof by reacting Compound (I), salt or solvate thereof with Compound (II) in a toluene solvent in the presence of an additive such as water or an alcohol. Also disclosed is a process for the preparation of Compound (IV) comprising hydrolyzing the obtained Compound (III) if necessary, and then oxidizing. | 10-23-2008 |
| 20080213759 | Novel Angiogenesis Inhibitor - Because AK022567 has angiogenesis inhibitory activity, it is useful as an angiogenesis inhibitor. Furthermore, 4 splicing variants obtained from the same gene are also useful as an angiogenesis inhibitor. These 5 polypeptides, polynucleotides encoding the polypeptides and antibodies against the polypeptides are useful for screening of a candidate compound as an angiogenesis inhibitor or promoter. A compound obtained from the screening is useful as a medicine and can be used for a preventive or therapeutic agent for an angiogenesis related disease. | 09-04-2008 |
